Panama

The primary regulatory authority for health products in Panama is the Direccion Nacional de Farmacia y Drogas (DNFD), operating under the Ministerio de Salud (MINSA). The overarching legal framework is established by Law 1 of 2001 and its subsequent regulatory decrees, which govern the registration, importation, commercialization, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and increasingly, digital health solutions. All health products intended for the Panamanian market must obtain a Registro Sanitario (sanitary registration) prior to commercialization, a process that involves technical dossier review, safety and efficacy assessment, and labeling compliance verification. The DNFD coordinates closely with the Caja de Seguro Social (CSS), Panama's social security health system, which also plays a significant role in product acceptance for the public sector.

Submission dossiers are generally expected to follow the Common Technical Document (CTD) format, and Panama recognizes reference approvals from stringent regulatory authorities such as the US FDA, EMA, and Health Canada, which can expedite the review process through an abbreviated or fast-track pathway. A local legal representative or registered commercial agent domiciled in Panama is mandatory for all foreign manufacturers seeking market authorization. Panama is a member of the Pan American Network for Drug Regulatory Harmonization (PANDRH) and has been progressively aligning its regulatory standards with regional harmonization initiatives. Recent reforms have focused on strengthening pharmacovigilance obligations, introducing specific frameworks for in vitro diagnostics and Class II-III medical devices, and developing preliminary guidelines for software-as-a-medical-device (SaMD) and digital health technologies.

Public procurement of health products in Panama is conducted through two principal institutional channels: MINSA, which manages primary and secondary public health facilities nationwide, and the Caja de Seguro Social (CSS), which operates its own extensive hospital network and serves Panama's formally employed population and their beneficiaries. Both institutions conduct independent procurement processes, resulting in a dual-track public market that suppliers must navigate separately. Tenders are governed by Law 22 of 2006 on Public Procurement and administered through the national electronic procurement platform, PanamaCompra, which provides transparency and public access to tender documents, awards, and supplier registrations. The Direccion General de Contrataciones Publicas (DGCP) oversees compliance with procurement regulations, and both MINSA and CSS periodically issue framework agreements and consolidated tenders for high-volume products to achieve economies of scale.

The private sector constitutes a significant portion of the health market in Panama, particularly in Panama City, where a well-developed network of private hospitals, clinics, and pharmacies serves a large insured and out-of-pocket population. Private procurement occurs through direct commercial negotiations with local distributors and importers, with no centralized framework governing private sector purchasing. Panama also benefits from donor-funded health programs, with organizations such as PAHO/WHO, UNICEF, and the US Centers for Disease Control and Prevention (CDC) supporting public health initiatives, particularly in areas such as communicable disease surveillance, maternal and child health, and HIV/AIDS. While Panama does not currently enforce explicit local manufacturing preference policies in procurement law, the government has expressed interest in strengthening domestic pharmaceutical production capacity, and registered local manufacturers may benefit from expedited administrative processes in practice.